Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study of tildrakizumab in hidradenitis suppurativa
2022-000706-10Phase 2Completed
- Sponsor
- University Medical Center Mainz
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tildrakizumab in hidradenitis suppurativa (HS), sponsored by University Medical Center Mainz. Primary endpoint: HiSCR50 at Week 20. Started May 2022; status: completed.
02
Drugs
tildrakizumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2022-000706-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000706-10.